Fate Therapeutics Inc is a clinical stage biopharmaceutical company focused on creating off the shelf cellular immunotherapies. The company uses an induced pluripotent stem cell platform to generate clonal master iPSC lines that serve as a renewable source for manufacturing uniform T cell and NK cell product candidates. These product candidates are engineered with synthetic controls such as chimeric antigen receptors and novel receptors designed to enhance safety, persistence and anti tumor activity. Fate Therapeutics intends to deliver therapies that can be administered without intense conditioning chemotherapy and accessed in outpatient or community settings. The induced pluripotent stem cell platform enables the creation of a clonal master iPSC line that can be differentiated into large numbers of T cells or NK cells under controlled conditions. This approach yields product candidates that are uniform in composition and free from donor variability. Fate Therapeutics has built a 40,000 plus square foot GMP manufacturing facility in San Diego to support clinical scale production. The company pipeline includes multiple iPSC derived CAR T cell and CAR NK cell candidates targeting autoimmune diseases and solid tumors.

Fate Therapeutics generates revenue primarily through collaborative agreements, licensing arrangements and milestone payments with pharmaceutical partners. The company has a collaboration with Ono Pharmaceutical that includes option exercise fees, research funding and potential future milestone and royalty payments tied to the development of iPSC derived CAR T cell and CAR NK cell product candidates for solid tumors. Under the Ono collaboration, Fate Therapeutics received an upfront payment of ten million dollars and subsequent option exercise payments totaling twelve point five million dollars. The agreement also includes annual research and development funding that could reach forty four point five million dollars over the term. Milestone payments tied to clinical, regulatory and commercial achievements may provide additional consideration up to eight hundred forty three million dollars, subject to certain reductions. In addition, Fate Therapeutics has received grant awards from institutions such as the California Institute for Regenerative Medicine to support clinical trials of its product candidates. Grant awards from the California Institute for Regenerative Medicine have provided seven point nine million dollars for the FT819 SLE trial and four million dollars for the FT836 solid tumor program. The company may also earn revenue from licensing its intellectual property to third parties and from any future commercial sales of approved therapies.

Fate Therapeutics occupies a niche in the cell therapy industry by pursuing an off the shelf approach based on induced pluripotent stem cells, which differs from the autologous cell therapy model used by many competitors. Companies such as Gilead Sciences, Bristol Myers Squibb and Novartis market autologous CAR T cell therapies for hematologic malignancies, while Allogene Therapeutics and Caribou Biosciences develop allogeneic NK or T cell products but still rely on donor derived cells. Fate Therapeutics competitive advantages include its proprietary clonal master iPSC lines that enable large scale, uniform manufacturing and its extensive synthetic control toolkit that aims to reduce reliance on conditioning chemotherapy. The firm also benefits from a broad patent portfolio covering iPSC engineering, gene editing and cell programming technologies. Many competitors rely on autologous approaches that require patient specific cell collection, manufacturing and delivery, which limits scalability and increases cost. Allogeneic alternatives from companies such as Fate Therapeutics use donor cells but still face challenges with variability and potential graft versus host disease. The company strategy of using clonal master iPSC lines aims to produce off the shelf products that can be stored, shipped and administered on demand. Its synthetic control toolkit includes receptors such as hnCD16, ADR and Sword & Shield technologies designed to enhance safety and reduce the need for conditioning chemotherapy. The broad patent estate covering iPSC derivation, gene editing and cell processing provides a barrier to entry and supports freedom to operate in multiple jurisdictions.

Fate Therapeutics serves clinical trial sites in the United States, the United Kingdom and the European Union where its product candidates are being evaluated for autoimmune diseases and solid tumors. The company collaborates with pharmaceutical partners such as Ono Pharmaceutical to co develop and co commercialize certain iPSC derived therapies. In the future, upon regulatory approval, the company expects to sell its treatments to hospitals, infusion centers and specialty clinics that treat patients with cancer or autoimmune conditions. Currently, the primary recipients of its technology are investigators and patients participating in its sponsored clinical studies. As of the November 2025 data cutoff, the FT819 SLE trial had activated fourteen clinical sites across the United States, United Kingdom and European Union. The FT825 solid tumor trial with Ono Pharmaceutical is enrolling patients at multiple centers in the United States. The FT836 program has initiated a Phase 1 study with sites anticipated to open in the United States. These clinical sites serve as the primary customers for the company's investigational product supply and medical support. In addition, the company works with contract manufacturing organizations and academic laboratories that provide specialized services for process development and analytical testing. Looking ahead, approved therapies would be purchased by healthcare systems, outpatient clinics and specialty treatment centers that manage patients with refractory cancer or severe autoimmune disease.